TL;DR
Neutrophil Extracellular Traps (NETs), once thought to be solely for fighting infections, are now implicated in the development and progression of cardiovascular diseases (CVD). This review synthesizes current research, highlighting how NETs contribute to atherosclerosis, endothelial damage, and thrombosis, and explores potential therapeutic strategies targeting NET formation for CVD treatment.
What Problem Does This Paper Address?
Cardiovascular diseases (CVDs), particularly atherosclerosis, are a leading cause of mortality worldwide. While inflammation is a known driver of atherosclerosis, the precise mechanisms by which immune cells contribute to its pathogenesis are still being unraveled. This paper addresses the emerging role of neutrophils and their unique defense mechanism, Neutrophil Extracellular Traps (NETs), in the context of CVD. Traditionally viewed as a protective response against pathogens, NETs are increasingly recognized as detrimental in non-infectious inflammatory conditions like atherosclerosis. The paper aims to consolidate the evidence linking NETs to CVD, elucidate their pathological roles, and discuss potential therapeutic interventions.
Methods
This paper is a comprehensive review, not an experimental study. It synthesizes findings from a wide range of existing research, including:
- Clinical studies: Examining NET levels in patients with CVD and correlating them with disease severity and adverse events.
- Basic research: Investigating the mechanisms of NET formation, release, and clearance in vitro and in animal models of atherosclerosis.
- Histological and immunohistochemical analyses: Detecting NETs within atherosclerotic plaques and thrombi.
- Molecular and cellular studies: Exploring the interactions between NETs and various cell types involved in atherosclerosis, such as endothelial cells, macrophages, and platelets.
The review also discusses various pathways and molecules regulating NET formation, including PAD4, NADPH oxidase, and calcium ionophores, as well as mechanisms of NET clearance, such as DNase I.
Datasets
Not discussed in the paper. This is a review article that synthesizes existing research rather than presenting new experimental data or datasets.
Key Insights and Ideas
- NETs are a double-edged sword: While crucial for fighting infections, NETs are pathologically involved in CVD, contributing to inflammation and tissue damage.
- Atherosclerosis is a NET-driven process: NETs are not just bystanders but active participants in the development of atherosclerotic plaques, promoting endothelial cell damage, macrophage activation, and platelet aggregation.
- NETs form a scaffold for thrombosis: The DNA and protein meshwork of NETs can trap blood components, facilitating clot formation and exacerbating cardiovascular events.
- Multiple pathways lead to NET formation: NETs can be triggered by various stimuli, including cholesterol crystals, oxidized LDL, and inflammatory signals, often converging on oxidative stress and PAD4 activation.
- Impaired NET clearance is problematic: Deficiencies in enzymes like DNase I, which degrade NETs, are linked to increased NET burden and worse cardiovascular outcomes.
- NETs are a promising therapeutic target: Inhibiting NET formation or enhancing their clearance presents a novel strategy for treating CVD.
Key Results
The review highlights several key findings from the literature:
- Clinical correlation: Elevated levels of NET components (e.g., double-stranded DNA, nucleosomes, MPO-DNA complexes) are associated with severe coronary stenosis and an increased risk of major adverse cardiovascular events (MACE).
- Histological evidence: NETs are found within atherosclerotic plaques and coronary arterial thrombi, often co-localized with activated platelets and extracellular iron.
- Mechanistic insights:
- NETs promote endothelial cell activation and dysfunction by increasing the expression of adhesion molecules.
- NETs prime macrophages for increased production of pro-inflammatory cytokines (IL-1β, IL-6), driving a Th17 cell response.
- NETs enhance platelet activation and aggregation, contributing to thrombus formation.
- Therapeutic potential:
- Inhibition of PAD4, a key enzyme in NET formation, has shown promise in reducing NETs and associated inflammation in preclinical models.
- Anticoagulants and statins may exert some of their cardiovascular benefits by suppressing platelet activation and NET formation.
- DNase I administration has been shown to reduce plaque NET content and remodel atherosclerotic plaques in animal models.
Limitations and Future Work
- Complexity of NET clearance: The precise mechanisms and factors regulating NET clearance are not fully understood, and impaired clearance is linked to various autoimmune disorders.
- Off-target effects of inhibitors: Current therapeutic strategies targeting NETs, such as pan-PAD inhibitors and DNase I, may have off-target effects, necessitating the development of more specific and targeted interventions.
- Antibiotic roles: The specific features and mechanisms by which certain antibiotics inhibit NET formation require further investigation.
- Future directions: The authors emphasize the need for further research to precisely control NET formation and identify specific molecular pathways for targeted therapeutic intervention. Understanding the intricate cross-talk between NETs and other cells in the atherosclerotic plaque is crucial for developing effective treatments.
Summary updated